Navigation Links
AMERIGROUP Announces Preliminary Third Quarter Results
Date:10/26/2009

hose on publicly funded healthcare programs by ensuring that these individuals enter an organized system of care and a true medical home. Serving approximately 1.7 million members in 11 states nationwide, AMERIGROUP accepts all eligible people regardless of age, sex, race or disability. The company's product offerings do not utilize any individual underwriting nor deny coverage due to pre-existing medical conditions. AMERIGROUP is dedicated to offering real solutions that improve healthcare access and quality for its members, while proactively working to reduce the overall cost of care to taxpayers. For more information and real story examples of these solutions, please visit www.amerigroupcorp.com.

Forward-Looking Statements

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the Securities and Exchange Commission's Fair Disclosure Regulation. This release contains certain ''forward-looking'' statements related to expected third quarter and annual 2009 earnings and medical costs, which are subject to numerous factors, many of which are outside of our control, including the severity of the flu season and the impact of the H1N1 virus, medical expense trend levels, our ability to manage our medical costs generally, seasonality of health benefits expenses, the levels and amounts of membership, revenues, organic premium revenues, rate increases, operating cash flows, health benefits expenses, selling, general and administrative expenses, days in claims payable, income tax rates, cash balances, earnings per share and net income growth. These statements are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to
'/>"/>

SOURCE AMERIGROUP Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 30
2. AMERIGROUP Corporation Names Two New Executives
3. AMERIGROUP Corporation to Host Investor Day
4. AMERIGROUP Foundation Honors Warehouse of Hope Founder Craig Parson as a Healthy Hero
5. AMERIGROUP Reports Q2 Net Income of $49.6 Million or $0.94 per Diluted Share, Including $0.43 per Diluted Share Positive Impact from Tax Adjustment
6. AMERIGROUP Public Policy Institute, Black Leadership Forum, Inc. Convene Summit to Examine Preterm Birth Policy Solutions
7. AMERIGROUP Corporation to Discuss Second Quarter Earnings on July 31
8. AMERIGROUP Corporation to Present at the 19th Annual Wachovia Mid-Year Equity Conference on June 24
9. Dr. Emily Abrams Massey of Atlanta Honored as Healthy Hero by the AMERIGROUP Foundation
10. AMERIGROUP Corporation to Present at The Deutsche Bank 34th Annual Healthcare Conference on May 18
11. AMERIGROUP Corporation to Webcast Annual Meeting of Stockholders on May 7, 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...explain why more blacks die than whites, study fin...-- Body weight and co-existing health problems don...wer survival rates than whites, U.S. researchers s... lower survival rates than whites for nearly all c...e explored a variety factors, such as differences ...
(Date:11/23/2009)....,Nov.23/PRNewswire/--HealthLeaders-InterStudy,ale...tsthatself-insuredmembercompaniesthatarepartofMilw...regatehealthcare-costdecreaseof1.5percentperhealth...gh-performanceprovidernetwork.Accordingtothe Milwa...uredmembercompaniessaved$44millioninhealthcarecost...
(Date:11/23/2009)...PRNewswire-FirstCall/--NewCardio,Inc.,(OTCBulletin...nouncedtodaythatCEO,Dr.BranislavVajdic,andCFO,Rich...erenceonThursday,December3rd,at4:30PMPSTattheLuxeS...lbeavailableforone-on-onemeetingsonWednesday,Decem...meeMaasat(646)536-7331or brett@haydenir.com torequ...
(Date:11/23/2009)...swire-FirstCall/--ArcadiaResources,Inc.(NYSEAmex: ...reservicesundertheArcadiaHealthCare(SM)()brand,ann...dsaleofsharesofitscommonstockandwarrantstopurchase...stitutionalinvestors,representinggrossproceedstoAr...rmsofseparateSubscriptionAgreementswiththeinvestor...
(Date:11/23/2009)...tion about Oxycodone use is now just a click away ...site is a statistical database that reports the s...ounty in the United States. The data is compiled b...eational or medicinal use. , ...egal and illegal Oxycodone statistics and inform...
Breaking Medicine News(10 mins):Health News:Weight May Not Drive Racial Disparities in Colon Cancer 2Health News:Milwaukee Employers See Cost Savings with High-Performance Provider Network 2Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 2Health News:NewCardio, Inc. to Present at 2nd Annual LD MICRO Conference 3Health News:Arcadia Resources Announces Closing of $11.1 Million Financing 2Health News:DopeStats.com Provides Statistics on Oxycodone Abused in Non-Medical Purposes 2
...nsible for nearly half (49 per cent) of all deaths...e each year. Reducing cholesterol is one of the mo... Both soy protein and plant sterols extracted fr... on cholesterol-lowering however recently the US s...
...omen to tobacco smoke causes genetic damage// in t... studies have shown that smoking during pregnancy ... can be detected at birth. Stephen G. Grant, ...from the earlier study and shows that passive - or...
...hildren getting affected by illnesses due to expos...from the figures of 1998 to 2002, reports a resear...pesticides in the school environment is a health r...erty, with some schools at risk of pesticide expos...
...Indian Medical Association (IMA) has today warned ...areful while treating or dealing with patients who...result of some of the Maoist violence taking place...sed anger and panic among doctors in North Bihar S...
...e stem cell therapy can be used successfully to tr...s University School of Medicine had showed that it... such a way. In just two months, stem cells... percent to 75 percent. The findings are t...
... of India is planning to incorporate penal provisi...ll 2005 to make licensed drug manufacturers who ar...cts in such a look-alike manner a criminal act. Of...uld be mistaken for the other drug under the defin...
Other Medicine News:Health News:Exposure to Pesticides in Schools Produces Illnesses Among Employees, Students 2Health News:Stem Cell Therapy For Treating Heart Attacks 2Health News:Clampdown On Fake Drugs Manufacturers In India – New Bill Enacte 2
(Date:11/23/2009)..., IRVINE,Calif.,Nov.23/PRNewswire/--AdvancedSte...ventionsolutionprovider,announcedtodaytheacquisiti...,aprivatelyhelddeveloperofinnovativedisinfectionpr...infections.Termsoftheacquisitionwerenotdisclosed. ...eadecontaminationtechnologythatprovidesdisinfectio...
(Date:11/20/2009)... , BOSTON, Nov. 20 The Uni... upheld an earlier District Court ruling yesterday...ge Wholesale Price (AWP) pharmaceutical litigation... (Logo: http://www.newscom.com/cgi-bin/prnh/20080...ment that awarded consumers who purchased the phar...
(Date:11/20/2009)... , LOUISVILLE, Ky., Nov. 20 /PRNewswire/ -...tigators (NADDI) today announced a new initiative ...rsor Log Exchange (NPLEx) is a multi-state electro...tions on over-the-counter (OTC) medicines containi...le. The technology for NPLEx is based on a system...
Breaking Medicine Technology:ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 2U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 3National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 2National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 1KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 4Scientists remove amyloid plaques from brains of live animals with Alzheimers disease 10367 1Scientists remove amyloid plaques from brains of live animals with Alzheimers disease 10367 2SAMHSA Honors The Soloist Greys Anatomy United States Of Tara and Mental Health Consumer Leaders at The Star Studded 2009 Voice Awards 59512 1SAMHSA Honors The Soloist Greys Anatomy United States Of Tara and Mental Health Consumer Leaders at The Star Studded 2009 Voice Awards 59512 2SAMHSA Honors The Soloist Greys Anatomy United States Of Tara and Mental Health Consumer Leaders at The Star Studded 2009 Voice Awards 59512 3SAMHSA Honors The Soloist Greys Anatomy United States Of Tara and Mental Health Consumer Leaders at The Star Studded 2009 Voice Awards 59512 4
...esented on Valopicitabine Combined,with an Investi...il 12, 2007 /PRNewswire-FirstCall/ --,Idenix Pharm...phase,IIb studies of the novel combination of valo...a (Pegasys(R)) in both treatment-naive,and treatme...e-1,strain of the hepatitis C virus (HCV). These d...
...osts of eradicating,poliomyelitis from the remaini...m, are much lower than the long term costs of tryi...a recently developed,monovalent vaccine is almost ...litis than an existing trivalent vaccine. These ar...d in an upcoming,issue of The Lancet. , Both Artic...
Other Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
FF 450plus IR
... for fast and easy operation with advanced lens me...utomatically held when the lens is properly aligne...The sophisticated alignment system guides you to c...designed with a small footprint, occupying little ...
CR6-45NM Non-Mydriatic Retinal Camera
TRC-50FXC
Medicine Products: